Table 2. Twenty-Three Genes Form the Prognostic Signature

Table 2. A total of 12 predictive genes selected for the weighted-voting outcome classifier of nonsquamous cell carcinomas

Table 3. A total of 12 predictive genes selected for the weighted-voting outcome classifier of squamous cell carcinomas

Table 1. A total of 25 predictive genes selected for the weighted-voting outcome classifier of NSCLCs

Table 3S. 218 genes differentially regulated in 8 recurrent versus 13 non-recurrent human prostate tumors

Table S2:  Functional categorization of 92 common genes over-expressed (>3 fold) in six huES cell linesa

Table 4. Analysis of 28 common genes overexpressed in pooled huES cell lines compared with EB by EST enumeration

Table 1 Gene expression signatures predicting survival of breast cancer patients

Table 2 Gene expression signatures predicting survival of breast cancer patients with estrogen receptor-negative tumors

Table 5 Differentially expressed genes in late relapse nonseminomatous germ cell tumor of testes (NSGCTT)s

Table 6 Differentially expressed genes in late relapse yolk sac tumors

Table 2 Differentially expressed genes in embryonal carcinoma

Table 3 Differentially expressed genes in teratoma

Table 4 Differentially expressed genes in primitive neuroectodermal tumor

Table 1 Differentially expressed genes in yolk sac tumor

Table 1. Representative example of genes transactivated by p53-D281G in H1299 cells

Table 2. Target genes tested; 27 xenobiotic-metabolizing target genes  the ESR1/ERalpha gene (coding for the ERalpha) and the MKI67 gene (coding for the proliferation-related Ki-67 antigen)

Table 4. Genes down-regulated more than 4-fold in the SDF versus FDF

Table 1. Genes up-regulated more than 2-fold in the CD34+/CD38- fraction versus CD34+/CD38+

Table 3. Genes up-regulated more than 4-fold in SDF versus FDF

Table 2. Genes down-regulated more 2-fold in the CD34+/CD38- fraction versus CD34+/CD38+

Table 2 Genes whose expression is significantly regulated by all six genotoxins at 4h